These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27498199)

  • 41. Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease.
    Schofield C; Chaudhuri KR; Carroll C; Sharma JC; Pavese N; Evans J; Foltynie T; Reichmann H; Zurowska L; Soares-da-Silva P; Lees A
    Neurodegener Dis Manag; 2022 Apr; 12(2):77-91. PubMed ID: 35313124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
    Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
    Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
    Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson's disease: Systematic review and network meta-analysis.
    Wu W; Lu X; Zhang L; Hong D
    Clin Neurol Neurosurg; 2024 Apr; 239():108189. PubMed ID: 38437773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    J Neural Transm (Vienna); 2021 Mar; 128(3):337-344. PubMed ID: 33630140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates.
    Metta V; Ibrahim H; Muralidharan N; Rodriguez K; Masagnay T; Mohan J; Lacsina A; Ahmed A; Benamer HTS; Chung-Faye G; Mrudula R; Falup-Pecurariu C; Rodriguez-Blazquez C; Borgohain R; Goyal V; Bhattacharya K; Chaudhuri KR
    J Neural Transm (Vienna); 2024 Jan; 131(1):25-30. PubMed ID: 37798410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Opicapone for the treatment of Parkinson's disease: a review.
    Feldman M; Margolesky J
    Int J Neurosci; 2023 May; 133(5):532-543. PubMed ID: 33980110
    [No Abstract]   [Full Text] [Related]  

  • 48. Tolcapone: a review of its use in the management of Parkinson's disease.
    Keating GM; Lyseng-Williamson KA
    CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial.
    Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Moreira J; Pereira A; Rocha JF; Soares-da-Silva P
    Neurol Ther; 2022 Sep; 11(3):1409-1425. PubMed ID: 35705887
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Objective assessment of the effects of opicapone in Parkinson's disease through kinematic analysis.
    Bologna M; Guerra A; Colella D; Birreci D; Costa D; Cannavacciuolo A; Angelini L; Paparella G; Antonini A; Berardelli A; Fabbrini G
    Neurol Sci; 2024 May; 45(5):2035-2046. PubMed ID: 38091213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations.
    Reichmann H; Eggert K; Oehlwein C; Warnecke T; Lees AJ; Kemmer M; Soares-da-Silva P
    Eur Neurol; 2022; 85(5):389-397. PubMed ID: 35350024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.
    Hauser RA; Videnovic A; Soares-da-Silva P; Liang GS; Olson K; Jen E; Rocha JF; Klepitskaya O
    Parkinsonism Relat Disord; 2024 Jun; 123():106971. PubMed ID: 38631081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.
    Leta V; van Wamelen DJ; Aureli F; Metta V; Trivedi D; Cortelli P; Rodriguez-Blazquez C; Rizos A; Ray Chaudhuri K
    J Neural Transm (Vienna); 2023 Jul; 130(7):925-930. PubMed ID: 37036498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study.
    Pinto R; l'Hostis P; Patat A; Homery MC; Falcão A; Nunes T; Rocha JF; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):454-62. PubMed ID: 27137718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.
    Hansen RN; Suh K; Serbin M; Yonan C; Sullivan SD
    J Med Econ; 2021; 24(1):563-569. PubMed ID: 33866942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Opicapone: Once-Daily COMT Inhibitor for the Treatment of Wearing Off in Parkinson's Disease.
    Craft BM; Baker DE; Levien TL
    Sr Care Pharm; 2022 Feb; 37(2):55-61. PubMed ID: 35082010
    [No Abstract]   [Full Text] [Related]  

  • 59. Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.
    Kitajima T; Mizote S; Bonifácio MJ; Umemura T; Yoneda K; Moser P; Soares-da-Silva P; Tanaka M
    Neuropharmacology; 2018 Dec; 143():282-288. PubMed ID: 30290160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
    Destée A; Rérat K; Bourdeix I
    Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.